SCHEMBL6080438

SCHEMBL6080438

CCOC(=O)c1nc2c(O)cccc2[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
KDM4E B2RXH2 4/20 0.46
ADORA3 P0DMS8 2/20 0.46
POLB P06746 1/20 0.45
CYP1A2 P05177 2/20 0.44
PARP1 P09874 2/20 0.44
MAP3K5 Q99683 1/20 0.44
CCR6 P51684 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
CHEK1 O14757 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
KDM5A P29375 1/20 0.43
KDM5B Q9UGL1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2779501 0.86 MAP3K5 (0.46) KDM4EADORA3POLBCYP1A2PARP1
SCHEMBL880365 0.80 ALDH1A1 (0.62) KDM4EADORA3POLBCYP1A2ALDH1A1
SCHEMBL6079636 0.79 GABRA1 (0.56) KDM4EADORA3ALDH1A1KMT2AHPGD
SCHEMBL6081154 0.79 GRIN1 (0.45) KDM4ECYP1A2PARP1KMT2AHPGD
SCHEMBL9704126 0.78 POLB (0.45) KDM4EADORA3POLBALDH1A1KMT2A
Butane SCHEMBL7847687 0.77 ALDH1A1 (0.60) KDM4EADORA3POLBCYP1A2ALDH1A1
SCHEMBL9703414 0.75 HTT (0.49) KDM4EADORA3L3MBTL1
SCHEMBL3237187 0.75 PARP1 (0.53) KDM4ECYP1A2PARP1KMT2AGAA
SCHEMBL11372106 0.74 ALDH1A1 (0.47) KDM4EPOLBALDH1A1KMT2ACHEK1
SCHEMBL9703959 0.74 KMT2A (0.54) KDM4EADORA3POLBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL CA12 3292/4885CA1 2702/4885CA2 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.